Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 6% – Should You Sell?

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) fell 6% during mid-day trading on Tuesday . The company traded as low as $23.60 and last traded at $23.7510. 151,163 shares changed hands during trading, a decline of 55% from the average session volume of 337,931 shares. The stock had previously closed at $25.28.

Analyst Ratings Changes

A number of research firms recently commented on ETON. B. Riley Financial raised their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. HC Wainwright increased their target price on Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a report on Friday, March 20th. Craig Hallum raised their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $39.33.

Eton Pharmaceuticals Stock Down 6.9%

The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. The firm has a market cap of $641.90 million, a PE ratio of -130.39 and a beta of 0.97. The business has a fifty day moving average price of $20.86 and a two-hundred day moving average price of $18.28.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The business had revenue of $21.28 million for the quarter, compared to analysts’ expectations of $20.58 million. On average, analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at $30,000. Quarry LP acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $44,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at $41,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $74,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.